Nifty
:
25461.30
Sensex
:
83442.50
0.30 (0.00%)
9.61 (0.01%)
Nifty
Sensex
:
:
25461.30
83442.50
0.30 (0.00%)
9.61 (0.01%)

Shilpa Medicare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
59/99

BSE: 530549 | NSE: SHILPAMED

NSE BSE
889.30
07-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  900
  •  914.95
  •  884
  •  896.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  34162
  •  30751936.85
  •  1000
  •  555

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 8,666.72
  • 110.70
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,224.56
  • 0.11%
  • 3.65

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.23%
  • 10.83%
  • 24.42%
  • FII
  • DII
  • Others
  • 10.97%
  • 6.13%
  • 3.42%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.49
  • 4.87
  • 0.18

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.44
  • 1.93
  • 3.66

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -8.04
  • -27.26
  • -19.30

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.18
  • 60.49
  • 74.05

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.65
  • 2.38
  • 2.20

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.37
  • 23.05
  • 23.24

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
3.67
8.04
28.15
39.7
P/E Ratio
242.32
110.61
31.59
22.40
Revenue
1152
1286
1671
1970
EBITDA
245
512
641
Net Income
32
78
277
389
ROA
1.1
14.2
15.8
P/B Ratio
3.60
3.29
2.87
ROE
1.77
11.05
13.75
FCFF
-140
146
304
FCFF Yield
-1.47
1.53
3.18
Net Debt
907
BVPS
246.85
270.45
309.65

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
330.81
291.69
13.41%
319.32
286.76
11.35%
343.80
312.98
9.85%
292.51
260.18
12.43%
Expenses
254.04
221.63
14.62%
238.62
220.53
8.20%
257.79
252.68
2.02%
218.91
212.26
3.13%
EBITDA
76.77
70.06
9.58%
80.69
66.23
21.83%
86.01
60.30
42.64%
73.60
47.92
53.59%
EBIDTM
23.21%
24.02%
25.27%
23.09%
25.02%
19.27%
25.16%
18.42%
Other Income
7.57
2.49
204.02%
1.13
1.94
-41.75%
4.99
1.81
175.69%
9.44
1.93
389.12%
Interest
14.49
24.20
-40.12%
11.75
26.22
-55.19%
25.55
23.24
9.94%
23.74
18.15
30.80%
Depreciation
28.79
26.63
8.11%
28.81
26.71
7.86%
28.28
27.79
1.76%
27.11
26.75
1.35%
PBT
12.97
27.85
-53.43%
41.27
15.23
170.98%
37.16
11.08
235.38%
32.20
4.95
550.51%
Tax
0.77
3.21
-76.01%
9.83
9.46
3.91%
18.83
7.60
147.76%
14.62
2.11
592.89%
PAT
12.21
24.64
-50.45%
31.44
5.77
444.89%
18.33
3.48
426.72%
17.58
2.84
519.01%
PATM
3.69%
8.45%
9.85%
2.01%
5.33%
1.11%
6.01%
1.09%
EPS
1.48
2.82
-47.52%
3.25
0.53
513.21%
1.83
0.19
863.16%
1.44
0.14
928.57%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
1,286.44
1,151.60
1,050.11
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
613.80
Net Sales Growth
11.71%
9.66%
-8.33%
27.12%
-0.75%
23.80%
-7.03%
1.24%
8.76%
16.72%
 
Cost Of Goods Sold
410.27
407.24
416.04
383.22
270.73
277.73
257.03
355.87
371.81
366.19
323.16
Gross Profit
876.17
744.36
634.07
762.30
630.40
630.18
476.36
432.95
407.36
350.25
290.63
GP Margin
68.11%
64.64%
60.38%
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
Total Expenditure
969.36
915.53
961.84
948.32
729.43
693.39
579.39
637.60
617.55
556.44
487.38
Power & Fuel Cost
-
52.41
56.79
52.43
40.25
38.76
33.57
28.86
26.30
21.90
19.29
% Of Sales
-
4.55%
5.41%
4.58%
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
Employee Cost
-
281.49
286.39
264.49
235.31
196.59
176.40
149.35
127.87
90.09
82.30
% Of Sales
-
24.44%
27.27%
23.09%
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
Manufacturing Exp.
-
82.69
110.32
124.11
91.29
79.19
61.23
59.96
52.55
45.35
36.55
% Of Sales
-
7.18%
10.51%
10.83%
10.13%
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
General & Admin Exp.
-
44.36
46.86
71.58
47.71
70.26
27.20
22.50
16.95
14.11
10.64
% Of Sales
-
3.85%
4.46%
6.25%
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
Selling & Distn. Exp.
-
20.91
18.56
18.02
18.63
10.40
6.72
6.37
4.75
7.27
5.99
% Of Sales
-
1.82%
1.77%
1.57%
2.07%
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
Miscellaneous Exp.
-
26.42
26.89
34.49
25.51
20.47
17.23
14.68
17.32
11.54
5.99
% Of Sales
-
2.29%
2.56%
3.01%
2.83%
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
EBITDA
317.07
236.07
88.27
197.20
171.70
214.52
154.00
151.23
161.61
159.99
126.42
EBITDA Margin
24.65%
20.50%
8.41%
17.21%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
Other Income
23.13
16.59
31.41
20.90
40.09
22.22
15.56
32.62
29.34
11.36
6.93
Interest
75.53
91.81
58.65
41.17
21.87
4.56
3.68
2.66
3.13
3.93
4.05
Depreciation
112.99
107.87
95.50
79.80
53.98
43.78
42.06
37.22
30.64
23.14
21.41
PBT
123.60
52.99
-34.47
97.13
135.95
188.40
123.82
143.96
157.17
144.28
107.89
Tax
44.05
22.39
-7.36
41.68
48.85
33.49
26.18
33.91
42.04
35.62
35.22
Tax Rate
35.64%
37.87%
21.35%
39.35%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
PAT
79.56
31.88
-32.48
60.66
147.78
156.50
120.28
112.43
113.71
109.84
73.69
PAT before Minority Interest
79.55
31.96
-30.92
60.58
146.20
154.91
117.52
110.05
110.59
106.24
72.62
Minority Interest
-0.01
-0.08
-1.56
0.08
1.58
1.59
2.76
2.38
3.12
3.60
1.07
PAT Margin
6.18%
2.77%
-3.09%
5.30%
16.40%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
PAT Growth
116.61%
-
-
-58.95%
-5.57%
30.11%
6.98%
-1.13%
3.52%
49.06%
 
EPS
8.13
3.26
-3.32
6.20
15.11
16.00
12.30
11.50
11.63
11.23
7.53

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
1,808.69
1,783.28
1,822.19
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
Share Capital
8.68
8.68
8.68
8.15
8.15
8.15
8.15
8.01
7.71
7.71
Total Reserves
1,800.01
1,774.60
1,813.51
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
Non-Current Liabilities
589.64
345.12
452.82
561.37
256.94
166.62
153.48
251.26
67.23
154.15
Secured Loans
560.16
242.92
353.49
473.87
164.48
80.39
67.09
141.20
0.03
71.03
Unsecured Loans
0.00
45.90
0.11
0.35
0.53
0.70
1.03
1.30
0.00
31.30
Long Term Provisions
22.43
17.65
19.08
15.48
26.17
21.77
20.32
16.89
13.96
11.75
Current Liabilities
693.35
784.45
611.54
543.29
410.82
253.44
265.84
236.90
222.07
189.06
Trade Payables
174.82
142.80
146.04
67.25
92.55
80.72
103.74
111.86
106.48
75.50
Other Current Liabilities
137.21
276.56
240.13
219.33
142.10
81.62
59.59
28.03
36.49
49.32
Short Term Borrowings
360.73
344.17
202.90
243.40
165.27
86.58
98.12
92.41
74.10
58.47
Short Term Provisions
20.58
20.92
22.46
13.31
10.89
4.52
4.39
4.60
5.00
5.77
Total Liabilities
3,082.94
2,903.93
2,875.50
2,572.16
1,989.21
1,610.02
1,499.13
1,472.22
930.89
904.54
Net Block
1,384.86
1,368.33
1,341.84
1,110.53
650.44
558.01
534.20
491.93
393.41
316.06
Gross Block
1,946.75
1,846.68
1,727.09
1,421.10
986.42
853.16
793.24
704.89
582.20
476.34
Accumulated Depreciation
561.89
478.35
385.25
310.57
335.98
295.15
259.04
212.96
188.79
160.28
Non Current Assets
2,206.12
2,134.37
1,988.30
1,729.60
1,365.35
1,064.96
827.16
742.33
576.68
576.77
Capital Work in Progress
718.78
655.33
506.18
541.29
666.25
429.12
209.85
140.51
91.90
221.62
Non Current Investment
39.91
42.66
34.23
21.22
10.45
2.25
20.79
27.99
34.15
0.19
Long Term Loans & Adv.
53.32
56.53
93.90
43.10
32.42
48.75
37.47
77.09
51.86
38.74
Other Non Current Assets
9.25
11.52
12.15
13.46
5.78
26.84
24.86
4.80
5.36
0.16
Current Assets
876.83
769.55
887.19
818.99
623.85
545.06
671.97
729.88
354.21
327.61
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
119.54
224.62
59.63
65.35
Inventories
344.93
319.82
355.24
316.84
226.43
187.67
188.71
190.00
134.23
130.78
Sundry Debtors
392.05
324.35
386.33
217.50
246.79
203.73
220.27
170.93
125.43
81.37
Cash & Bank
30.44
21.56
34.11
123.11
44.56
94.54
73.83
100.39
11.03
18.42
Other Current Assets
109.42
15.53
9.36
98.73
106.06
59.12
69.62
43.95
23.90
31.69
Short Term Loans & Adv.
90.60
88.29
102.16
62.81
29.25
14.08
43.54
21.95
8.90
4.91
Net Current Assets
183.48
-14.89
275.66
275.69
213.04
291.62
406.13
492.98
132.14
138.55
Total Assets
3,082.95
2,903.92
2,875.49
2,548.59
1,989.20
1,610.02
1,499.13
1,472.21
930.89
904.54

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
135.34
179.92
105.13
46.93
124.38
146.78
44.92
37.48
128.70
68.81
PBT
54.34
-38.28
102.26
196.79
188.40
143.70
136.77
146.49
140.36
107.84
Adjustment
205.77
147.81
109.34
4.03
41.32
20.44
18.83
17.19
20.61
26.46
Changes in Working Capital
-83.62
102.77
-71.99
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
-40.11
Cash after chg. in Working capital
176.49
212.30
139.62
94.53
166.57
182.85
85.94
71.08
158.27
94.19
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-41.15
-32.37
-34.48
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-166.58
-232.61
-285.50
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
-195.18
Net Fixed Assets
-17.18
-22.18
384.16
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
Net Investments
-2.53
-6.42
-18.18
-125.84
-4.44
141.85
95.51
-172.72
-14.09
-64.38
Others
-146.87
-204.01
-651.48
-6.42
-280.80
-81.05
32.48
82.72
-2.97
-52.34
Cash from Financing Activity
46.77
45.80
82.86
436.37
175.50
10.06
-60.91
312.70
-19.65
135.05
Net Cash Inflow / Outflow
15.53
-6.89
-97.51
79.03
10.36
-39.32
-24.75
87.95
-0.15
8.68
Opening Cash & Equivalents
19.07
25.62
122.85
44.31
34.13
73.83
99.97
7.05
3.61
9.19
Closing Cash & Equivalent
30.43
19.07
25.34
123.34
44.31
34.36
73.83
99.97
6.43
18.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
208.37
205.44
209.93
181.37
163.06
146.89
133.09
123.17
82.91
70.92
ROA
1.07%
-1.07%
2.20%
6.33%
8.61%
7.56%
7.41%
9.20%
11.58%
9.18%
ROE
1.78%
-1.71%
3.67%
10.41%
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
ROCE
5.49%
0.80%
5.94%
10.73%
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
Fixed Asset Turnover
0.61
0.59
0.73
0.75
0.99
0.89
1.06
1.22
1.36
1.34
Receivable days
113.53
123.51
98.75
94.03
90.56
105.51
90.20
69.00
52.26
43.99
Inventory Days
105.35
117.32
109.68
110.03
83.24
93.66
87.32
75.49
66.97
74.84
Payable days
142.34
126.70
106.00
107.72
47.69
58.00
61.51
60.89
60.10
62.86
Cash Conversion Cycle
76.54
114.12
102.43
96.33
126.11
141.17
116.00
83.61
59.13
55.97
Total Debt/Equity
0.52
0.45
0.37
0.57
0.29
0.16
0.18
0.24
0.14
0.34
Interest Cover
1.59
0.35
3.48
9.92
42.34
40.09
55.10
49.69
37.07
27.63

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Shilpa Medicare’s arm completes GMP inspection from Brazilian regulatory authority
    7th Jul 2025, 12:51 PM

    The audit was carried out between June 30 to July 4, 2025 and has been concluded with No Critical and No Major observations

    Read More
  • Shilpa Medicare - Quarterly Results
    26th May 2025, 17:49 PM

    Read More
  • Shilpa Medicare’s arm enters into strategic partnership with Orion Corporation
    23rd May 2025, 15:51 PM

    Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s Recombinant Human Albumin in Europe

    Read More
  • USFDA issues EIR to unit-1 of Shilpa Medicare’s arm
    15th May 2025, 10:08 AM

    The inspection was carried out at unit-1 by USFDA between March 3 to March 7, 2025

    Read More
  • Shilpa Medicare receives GMP approval from European Medicines Agency
    6th May 2025, 12:59 PM

    The company has received GMP approval for its Unit VI located at Bengaluru, Karnataka

    Read More
  • Shilpa Medicare gets USFDA’s approval for Varenicline Tablets
    9th Apr 2025, 17:12 PM

    The total US market for this product is around $203 million.

    Read More
  • Shilpa Medicare’s marketing partner launches BORUZU in US market
    3rd Apr 2025, 15:40 PM

    The product has already been granted permanent J-code by U.S. Centers for Medicare & Medicaid Services

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.